ATE453727T1 - Sequenzen des t-zellrezeptors cdr3 und nachweisverfahren - Google Patents

Sequenzen des t-zellrezeptors cdr3 und nachweisverfahren

Info

Publication number: ATE453727T1
Authority: AT; Austria
Prior art keywords: sequences; cell receptor; detection methods; receptor cdr3; disclosed
Prior art date: 2002-06-05

Application number

AT03736888T

Other languages

English (en)

Inventor

Jingwu Zhang

Original Assignee

Baylor College Medicine

Opexa Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-06-05

Filing date

2003-06-05

Publication date

2010-01-15

2003-06-05 Application filed by Baylor College Medicine, Opexa Pharmaceuticals Inc filed Critical Baylor College Medicine

2010-01-15 Application granted granted Critical

2010-01-15 Publication of ATE453727T1 publication Critical patent/ATE453727T1/de

Links

108091008874 T cell receptors Proteins 0.000 title abstract 3
102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 3
238000001514 detection method Methods 0.000 title 1
201000006417 multiple sclerosis Diseases 0.000 abstract 3
208000023275 Autoimmune disease Diseases 0.000 abstract 2
108090000765 processed proteins & peptides Proteins 0.000 abstract 2
206010039073 rheumatoid arthritis Diseases 0.000 abstract 2
238000000034 method Methods 0.000 abstract 1
238000012544 monitoring process Methods 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
108020004707 nucleic acids Proteins 0.000 abstract 1
150000007523 nucleic acids Chemical group 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Immunology (AREA)
Diabetes (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Neurology (AREA)
Rheumatology (AREA)
Biophysics (AREA)
Endocrinology (AREA)
Biochemistry (AREA)
Wood Science & Technology (AREA)
Molecular Biology (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Pathology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Neurosurgery (AREA)
General Engineering & Computer Science (AREA)

AT03736888T 2002-06-05 2003-06-05 Sequenzen des t-zellrezeptors cdr3 und nachweisverfahren ATE453727T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US38628702P	2002-06-05	2002-06-05
PCT/US2003/017873 WO2003104407A2 (en)	2002-06-05	2003-06-05	T cell receptor cdr3 sequences and methods for detection

Publications (1)

Publication Number	Publication Date
ATE453727T1 true ATE453727T1 (de)	2010-01-15

Family

ID=29736145

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03736888T ATE453727T1 (de)	2002-06-05	2003-06-05	Sequenzen des t-zellrezeptors cdr3 und nachweisverfahren

Country Status (16)

Country	Link
EP (1)	EP1530483B1 (de)
JP (3)	JP2005528910A (de)
CN (1)	CN1674931A (de)
AT (1)	ATE453727T1 (de)
AU (1)	AU2003237437B2 (de)
BR (1)	BR0311578A (de)
CA (1)	CA2485874A1 (de)
DE (1)	DE60330780D1 (de)
IL (2)	IL165194A (de)
MX (1)	MXPA04011646A (de)
NO (1)	NO20044945L (de)
NZ (1)	NZ537403A (de)
PL (1)	PL213315B1 (de)
RU (1)	RU2004139045A (de)
WO (1)	WO2003104407A2 (de)
ZA (1)	ZA200409792B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE536867T1 (de)	2006-03-16	2011-12-15	Tris Pharma Inc	Modifizierte freisetzungsformulierungen mit arznei-ion-austausch-harzkomplexen
CA2880456A1 (en)	2012-08-15	2014-02-20	Tris Pharma, Inc.	Methylphenidate extended release chewable tablet
US11590228B1 (en)	2015-09-08	2023-02-28	Tris Pharma, Inc	Extended release amphetamine compositions
CN108070644B (zh) *	2016-11-08	2021-06-29	国家卫生计生委科学技术研究所	一种妊娠高血压的诊断系统
US11858994B2 (en)	2017-03-15	2024-01-02	Repertoire Genesis Incorporation	Biomarkers for cancer immunotherapy
US12458592B1 (en)	2017-09-24	2025-11-04	Tris Pharma, Inc.	Extended release amphetamine tablets
US11590081B1 (en)	2017-09-24	2023-02-28	Tris Pharma, Inc	Extended release amphetamine tablets

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL97709A (en) *	1990-03-30	2005-05-17	Brigham & Womens Hospital	Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis
AU774952B2 (en) *	1999-02-23	2004-07-15	Baylor College Of Medicine	T cell receptor Vbeta-Dbeta-Jbeta sequence and methods for its detection

2003
- 2003-06-05 PL PL374723A patent/PL213315B1/pl unknown
- 2003-06-05 BR BRPI0311578-0A patent/BR0311578A/pt not_active IP Right Cessation
- 2003-06-05 AU AU2003237437A patent/AU2003237437B2/en not_active Ceased
- 2003-06-05 AT AT03736888T patent/ATE453727T1/de not_active IP Right Cessation
- 2003-06-05 EP EP03736888A patent/EP1530483B1/de not_active Expired - Lifetime
- 2003-06-05 RU RU2004139045/13A patent/RU2004139045A/ru not_active Application Discontinuation
- 2003-06-05 NZ NZ537403A patent/NZ537403A/en not_active IP Right Cessation
- 2003-06-05 JP JP2004511467A patent/JP2005528910A/ja not_active Withdrawn
- 2003-06-05 DE DE60330780T patent/DE60330780D1/de not_active Expired - Lifetime
- 2003-06-05 CA CA002485874A patent/CA2485874A1/en not_active Abandoned
- 2003-06-05 CN CNA038186314A patent/CN1674931A/zh active Pending
- 2003-06-05 MX MXPA04011646A patent/MXPA04011646A/es not_active Application Discontinuation
- 2003-06-05 WO PCT/US2003/017873 patent/WO2003104407A2/en not_active Ceased
2004
- 2004-11-12 NO NO20044945A patent/NO20044945L/no not_active Application Discontinuation
- 2004-11-14 IL IL165194A patent/IL165194A/en not_active IP Right Cessation
- 2004-12-02 ZA ZA200409792A patent/ZA200409792B/en unknown
2010
- 2010-04-01 JP JP2010085593A patent/JP2010207226A/ja not_active Withdrawn
- 2010-06-27 IL IL206650A patent/IL206650A/en not_active IP Right Cessation
2013
- 2013-03-05 JP JP2013042552A patent/JP2013126420A/ja active Pending

Also Published As

Publication number	Publication date
IL165194A (en)	2010-11-30
CN1674931A (zh)	2005-09-28
BR0311578A (pt)	2007-04-27
NO20044945L (no)	2004-12-28
CA2485874A1 (en)	2003-12-18
IL206650A0 (en)	2011-07-31
ZA200409792B (en)	2006-07-26
EP1530483A4 (de)	2006-05-17
IL206650A (en)	2016-10-31
DE60330780D1 (de)	2010-02-11
WO2003104407A2 (en)	2003-12-18
JP2005528910A (ja)	2005-09-29
MXPA04011646A (es)	2005-03-07
EP1530483B1 (de)	2009-12-30
RU2004139045A (ru)	2005-09-10
JP2010207226A (ja)	2010-09-24
NZ537403A (en)	2009-10-30
EP1530483A2 (de)	2005-05-18
JP2013126420A (ja)	2013-06-27
PL374723A1 (en)	2005-10-31
WO2003104407A3 (en)	2005-03-24
AU2003237437A1 (en)	2003-12-22
PL213315B1 (pl)	2013-02-28
IL165194A0 (en)	2005-12-18
AU2003237437B2 (en)	2010-11-25

Legal Events

Date	Code	Title	Description
2010-06-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
Graham et al.	2020	Pathway paradigms revealed from the genetics of inflammatory bowel disease
IL206650A0 (en)	2011-07-31	T cell receptor cdr3 peptide for treating an autoimmune disease
ATE283289T1 (de)	2004-12-15	Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten
TW200616657A (en)	2006-06-01	Therapeutic peptides and method
EA200300381A1 (ru)	2003-10-30	Нуклеиновые кислоты и полипептиды нового рецептора
WO2005005651A3 (en)	2005-11-03	T cell receptor sequence and method for detecting and treating rheumatoid arthritis
AU778115B2 (en)	2004-11-18	Hybrid peptides modulate the immune response
ATE293169T1 (de)	2005-04-15	Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen
ATE417103T1 (de)	2008-12-15	Zellulärer rezeptor für hiv-1 vpr essentiell zum g2-m übergang des zellzyklus
ATE306498T1 (de)	2005-10-15	Von zellen präsentierte peptide
ATE304052T1 (de)	2005-09-15	Humane checkpointkinase, hcds1, zusammensetzungen und verfahren
DE69931482D1 (de)	2006-06-29	Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
WO2003072598A3 (en)	2003-12-24	Hsp70-derived peptides an uses thereof in the diagnosis and treatment of autoimmune diseases
DK1417222T3 (da)	2010-12-13	Isolerede polypeptider baseret på den neutraliserende epitop af p17-proteinet fra HIV egnet til vacciner samt neutraliserende anti-p17-antistoffer, der specifikt genkender nævnte neutraliserende epitop
ATE534669T1 (de)	2011-12-15	Verfahren zum erhalten von anti-idiotyp antikörpern
EP2192407A3 (de)	2011-04-27	Verfahren zum Nachweis von Zellimmunität und ihre Anwendung auf Arzneimittel
DK1436320T3 (da)	2011-06-27	T-celle-epitoper af cyn D 1-allergenet fra bermudagræspollen
EP1523548A4 (de)	2006-03-08	Für alkalische a-galactosidasen codierende polynukleotidsequenzen und verfahren zur verwendung davon
TR200100175T2 (tr)	2001-09-21	Otoimmün hastalıkların immünoterapisinde kullanılmak üzere yeni peptitler.
HUP0301111A2 (hu)	2003-08-28	Potenciálisan immundomináns acetilkolin-receptor oligopeptideket tartalmazó gyógyszerkészítmények és alkalmazásuk
EP1796707A4 (de)	2009-09-09	Peptide mit spezifischem sitz in herzgefässen und verwandte konjugate und verfahren
DK1569961T3 (da)	2010-04-12	Splice variant af det menneskelige hypofysevæksthormon
EP1986011A3 (de)	2011-04-13	Durch eine CD4+-T-Lymphozyten fördernde Krankheit erkannte Peptidepitope
GB0426960D0 (en)	2005-01-12	TGR-3 like protein receptor
AU4956901A (en)	2001-10-08	Novel human 7tm proteins and polynucleotides encoding the same